OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or Mutations
Holly Soares, Mary Lynn Baniecki, Rhonda D. Cardin, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 13
Holly Soares, Mary Lynn Baniecki, Rhonda D. Cardin, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 13
Showing 13 citing articles:
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
An explanation for SARS-CoV-2 rebound after Paxlovid treatment
Alan S. Perelson, Ruy M. Ribeiro, Tin Phan
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31
Alan S. Perelson, Ruy M. Ribeiro, Tin Phan
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Viral and Symptom Rebound in Untreated COVID-19 Infection
Rinki Deo, Manish C. Choudhary, Carlee Moser, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 19
Rinki Deo, Manish C. Choudhary, Carlee Moser, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 19
COVID rebound is surprisingly common — even without Paxlovid
Ewen Callaway
Nature (2022)
Closed Access | Times Cited: 13
Ewen Callaway
Nature (2022)
Closed Access | Times Cited: 13
Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
Hannah A. Blair
Drugs & Therapy Perspectives (2022) Vol. 39, Iss. 2, pp. 41-47
Open Access | Times Cited: 12
Hannah A. Blair
Drugs & Therapy Perspectives (2022) Vol. 39, Iss. 2, pp. 41-47
Open Access | Times Cited: 12
Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States
Fuhan Yang, Thu Nguyen-Anh Tran, Emily Howerton, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Fuhan Yang, Thu Nguyen-Anh Tran, Emily Howerton, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States
Fuhan Yang, Thu Nguyen-Anh Tran, Emily Howerton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Fuhan Yang, Thu Nguyen-Anh Tran, Emily Howerton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Antiviral therapy for COVID-19
Adamantia Liapikou, Μαρία Λερίκου
European Respiratory Society eBooks (2024)
Closed Access
Adamantia Liapikou, Μαρία Λερίκου
European Respiratory Society eBooks (2024)
Closed Access
A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases
Charles L. Bennett, Joseph Magagnoli, Krishna Gundabolu, et al.
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0308205-e0308205
Open Access
Charles L. Bennett, Joseph Magagnoli, Krishna Gundabolu, et al.
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0308205-e0308205
Open Access
Nirmatrelvir treatment blunts the development of antiviral adaptive immune responses in SARS-CoV-2 infected mice
Valeria Fumagalli, Pietro Di Lucia, Micol Ravà, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Valeria Fumagalli, Pietro Di Lucia, Micol Ravà, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
REAL-WORLD EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR ON COVID-19-ASSOCIATED HOSPITALIZATION PREVENTION: A POPULATION-BASED COHORT STUDY IN THE PROVINCE OF QUÉBEC, CANADA
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
